FibroBiologics, Other Stockholder Equity vs Total Assets Analysis
| FBLG Stock | 2.15 0.01 0.46% |
FibroBiologics, Common financial indicator trend analysis is much more than just examining FibroBiologics, Common latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether FibroBiologics, Common is a good investment. Please check the relationship between FibroBiologics, Common Other Stockholder Equity and its Total Assets accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Other Stockholder Equity vs Total Assets
Other Stockholder Equity vs Total Assets Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of FibroBiologics, Common Other Stockholder Equity account and Total Assets. At this time, the significance of the direction appears to have almost identical trend.
The correlation between FibroBiologics, Common's Other Stockholder Equity and Total Assets is 0.94. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Total Assets in the same time period over historical financial statements of FibroBiologics, Common Stock, assuming nothing else is changed. The correlation between historical values of FibroBiologics, Common's Other Stockholder Equity and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of FibroBiologics, Common Stock are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Other Stockholder Equity i.e., FibroBiologics, Common's Other Stockholder Equity and Total Assets go up and down completely randomly.
Correlation Coefficient | 0.94 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Other Stockholder Equity
Total Assets
Total assets refers to the total amount of FibroBiologics, Common assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in FibroBiologics, Common books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Most indicators from FibroBiologics, Common's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into FibroBiologics, Common current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At this time, FibroBiologics, Common's Issuance Of Capital Stock is most likely to increase significantly in the upcoming years. The FibroBiologics, Common's current Enterprise Value is estimated to increase to about 1 B, while Selling General Administrative is projected to decrease to roughly 2.9 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 1.6M | 4.4M | 8.9M | 9.3M | Research Development | 521K | 1.1M | 2.4M | 1.3M |
FibroBiologics, Common fundamental ratios Correlations
Click cells to compare fundamentals
FibroBiologics, Common Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Currently Active Assets on Macroaxis
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroBiologics, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.55) | Return On Assets (0.66) | Return On Equity (2.68) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.